Significant survival gains with atezolizumab for NSCLC

Share :
Published: 9 Oct 2016
Views: 2375
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Dr Barlesi speaks with ecancertv at ESMO 2016 about results from the OAK study, in which 1225 non-small cell lung cancer patients who had previously received treatment were stratified based on PD-L1 status and treatment history, then received either PD-1 inhibitor atezolizumab or standard therapy docetaxel.

He describes the improvements in patients median survival across both groups, though reports a 56% greater response for patients with the highest levels of PD-L1 expression, and considers the treatment duration and associated toxicities of both arms in the trial.

Press conference footage of Dr Barlesi announcing these results is available here. 

Further details are available through news coverage here.

PD-1/PD-L1 targeting in lung cancer was also the focus of ESMO 2016 presentations from ESMO 2016 presentations from Dr Martin Reck and Dr Corey Langer, who spoke with ecancer about their work.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.